IBD: short, randomized trial of low-FODMAP diet yields promising outcomes

  • Bodini G & al.
  • Nutrition
  • 1 Jul 2019

  • International Clinical Digest
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • In patients with IBD, a brief switch to a low-FODMAP diet (LFD) was tied to reduced inflammatory markers and improved disease activity and QoL measures in this randomized trial.

Why this matters

  • FODMAPs have been implicated in symptoms related to irritable bowel syndrome (IBS), and recent findings have pointed to some benefit of a low FODMAP diet for IBD.

Key results

  • After 6 weeks, disease activity scores decreased with LFD vs standard diet (SD) (P=.024) among those with Crohn’s disease.
  • Median (interquartile range) calprotectin values also decreased in the LFD group from 76.6 (50-286.3) at baseline to 50 (50.6-81) mg/kg at 6 weeks (P=.004).
  • Such a decrease was not seen with SD.
  • Median disease-specific QoL scores increased significantly in the LFD group (P=.05) but did not change with the SD. 

Study design

  • 55 patients with IBD (in remission or with mild activity) were randomly allocated to LFD or SD for 6 weeks.
  • Measures used for disease activity were the Harvey-Bradshaw index (Crohn’s) and partial Mayo score (ulcerative colitis). 
  • Funding: None disclosed.

Limitations

  • Short trial, small numbers enrolled.

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

Submit